INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10583711
iling Date		2006-06-20
First Named Inventor Stina		GRONQVIST
Art Unit		
Examiner Name		
Attorney Docket Number		Q95503

				U.S.	PATENTS	Remove
		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6319361	B1	2001-11-20	Smith et al.	
	2	5035772	A	1991-07-30	Agnemo et al.	
	3	6599326	B1	2003-07-29	Seltzer et al.	
	4	5846788	A	1998-12-08	Pedersen et al.	
	5	5120776	A	1992-06-09	Rajetal.	
	6	5008310	A	1991-04-16	Beshay	
	7	4045595	A	1977-08-30	Chiu et al.	
	8	5211810	A	1993-05-18	Bartholomew et al.	

## | INFORMATION DISCLOSURE | Find Date | 2006-06-20 | | STATEMENT BY APPLICANT | (Not for submission under 37 CFR 1.99) | Examiner Name | |

Application Number			10583711
Filing Date			2006-06-20
	First Named Inventor Stina		GRONQVIST
	Art Unit		
	Examiner Name		
	Attorney Docket Number		Q95503

			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		name of Patentee or Applicant		Pages,Columns,Lines who Relevant Passages or Re Figures Appear			
	1	20020005634	A1	2002-01-17		Alb et al.					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	. Add		_
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	тя
	1	0685593	EP		A2	1995-12-06	Kimberty-Clark Co	mp (	W/English	Abstract	
	2	1106732	EP		A2	2001-06-13	National Starch & Chemical Investme Holding Corp	ent	W/English	Abstract	
	3	0294231	EP		A1	1988-12-07	Montclair State Co	lege	W/English	Abstract	
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
		_	NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs				
	1						_				
If you wis	h to a	l dd additional non-paten	t literatu	re docu	ment cit	ation informati	ion please click the	Add h	utton Ac	id	_

Application Number		10583711
Filing Date		2006-06-20
First Named Inventor Stina		GRONQVIST
Art Unit		
Examiner Name		
Attorney Docket Numb	er	Q95503
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Stina Art Unit

Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kin Codes of USPTO Patent Documents at year LISPTO,GOV or MPEP 901.6. Firster office that issued to document, by the ho-letter code (WIPO Standard ST3.3 For Juapense plateful accounted), the validation of the year of the Proprior mater procedule the serial number of the plateful accounted. If Anni of document by the appropriate symbols as exclusived on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English language translation is attached.

# Application Number | 10583711 | Filing Date | 2006-06-20 | Filing Date | 2006-06-20 | The Number | 10583711 | Filing Date | 2006-06-20 | The Number | 2006-06-20 | The Number | 2006-06-20 | The Number | 2006-07-10 | The Number

### Attorney Docket Number C

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/1(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

.7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Gordon Kit/	Date (YYYY-MM-DD)	2006-10-02
Name/Print	Gordon Kit	Registration Number	30764

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.